ADARx Pharmaceuticals, Inc.

ADARx Pharmaceuticals, Inc. が 2026年11月12日 に発表した内容

企業自身の 8-K から。

経営陣の発言

“We have made significant progress across our pipeline of next-generation siRNA therapeutics, bolstered by the successful completion of our IPO and concurrent private placement. These financings provide the resources to advance three clinical-stage programs in parallel, bring two advanced preclinical candidates into the clinic, and support additional IND filings as we expand our pipeline,”

発表資料から逐語で引用し、書類が氏名のある人物に帰属させている場合にのみ表示します。

ADARx Pharmaceuticals, Inc. の事業内容

ADARx Pharmaceuticals, Inc. is a late-clinical stage biotechnology company focused on developing next-generation RNA therapeutics designed to treat a broad spectrum of diseases. The Company is focused on advancing and expanding its pipeline of highly potent, selective and durable small interfering RNA (“siRNA”) therapeutic candidates, including three clinical-stage programs and two advanced preclinical programs. ADARx’s three hepatic-targeted programs are agazisiran, onvuzosiran and ADX-626, and its two extrahepatic-targeted programs are ADX-077 and ADX-199. Beyond its named programs, ADARx plans to continue to leverage its proprietary technologies to strategically expand its pipeline of next-generation siRNA therapeutics. ADARx’s goal is to control the expression of specific disease drivers with highly selective RNA targeted therapies, delivering life-changing treatments for patients with urgent unmet medical needs.

発表資料の末尾に記載された、企業自身による説明です。